ACE2 and cardiac hypertrophy: In addition, the pharmacologic inhibition of ACE2 exacerbates cardiac hypertrophy and circulating Ang(1–7) levels in transgenic rats are associated with reduced cardiac hypertrophy and fibrosis following isoproterenol infusion.